Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective study of added value of florastamin (18F) PET/CT in localisation of clinically significant prostate cancer in patients with PI-RADS≤3 report of multi-parametric MRI, elevated serum PSA levels and/or PSA density and with clinical suspicion of prostate cancer

Next Previous
Trial Profile

Prospective study of added value of florastamin (18F) PET/CT in localisation of clinically significant prostate cancer in patients with PI-RADS≤3 report of multi-parametric MRI, elevated serum PSA levels and/or PSA density and with clinical suspicion of prostate cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs F-18 Florastamin (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use; Registrational
  • Sponsors FutureChem; IASON

Most Recent Events

  • 12 Mar 2025 Status changed from recruiting to active, no longer recruiting.
  • 22 Aug 2024 Last checked against European Clinical Trials Database record.
  • 25 Apr 2024 Planned End Date changed from 27 Jun 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top